CIBC Private Wealth Group
CRSP icon

CIBC Private Wealth Group’s CRISPR Therapeutics CRSP Stock Holding History

CIBC Private Wealth Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$99.5K Sell
1,898
-183
-9% -$11K ﹤0.01% 1515
2025
Q3 		$135K Sell
2,081
-893
-30% -$51.3K ﹤0.01% 1352
2025
Q2 		$145K Buy
2,974
+979
+49% +$37.9K ﹤0.01% 1246
2025
Q1 		$62.4K Buy
1,995
+650
+48% +$27.6K ﹤0.01% 1553
2024
Q4 		$55.5K Hold
1,345
– – ﹤0.01% 1646
2024
Q3 		$63.2K Hold
1,345
– – ﹤0.01% 1687
2024
Q2 		$71.6K Sell
1,345
-269
-17% -$15.6K ﹤0.01% 1528
2024
Q1 		$110K Sell
1,614
-10,781
-87% -$772K ﹤0.01% 1356
2023
Q4 		$776K Buy
+12,395
New +$685K ﹤0.01% 693
2022
Q4 		– Sell
-5,520
Closed -$361K – 872
2022
Q3 		$361K Hold
5,520
– – ﹤0.01% 759
2022
Q2 		$335K Hold
5,520
– – ﹤0.01% 776
2022
Q1 		$346K Sell
5,520
-89
-2% -$5.59K ﹤0.01% 823
2021
Q4 		$425K Sell
5,609
-140
-2% -$12.2K ﹤0.01% 802
2021
Q3 		$643K Sell
5,749
-10,575
-65% -$1.33M ﹤0.01% 696
2021
Q2 		$2.64M Sell
16,324
-14,481
-47% -$1.76M 0.01% 487
2021
Q1 		$3.75M Buy
30,805
+24,735
+407% +$3.73M 0.01% 433
2020
Q4 		$929K Sell
6,070
-230
-4% -$27.2K ﹤0.01% 647
2020
Q3 		$527K Buy
+6,300
New +$559K ﹤0.01% 676
2020
Q2 		– Sell
-4,890
Closed -$207K – 637
2020
Q1 		$207K Buy
4,890
+500
+11% +$25.8K ﹤0.01% 796
2019
Q4 		$267K Buy
+4,390
New +$240K ﹤0.01% 820
2018
Q3 		– Sell
-385
Closed -$23K – 1113
2018
Q2 		$23K Sell
385
-140
-27% -$7.98K ﹤0.01% 1362
2018
Q1 		$24K Buy
+525
New +$21.7K ﹤0.01% 1341

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIBC Private Wealth Group's CRSP Position: Q4 2025 in Review

CIBC Private Wealth Group reduced its CRISPR Therapeutics (CRSP) stake by 8.8% in Q4 2025, selling an estimated $11K and leaving 1,898 shares worth $99.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1515.

CIBC Private Wealth Group first reported a position in CRSP in Q1 2018 and has held it in 22 quarters since. The position peaked at $3.75M in Q1 2021. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • CIBC Private Wealth Group held 1,898 shares of CRISPR Therapeutics worth $99.5K as of Q4 2025.
  • CIBC Private Wealth Group sold 183 CRISPR Therapeutics shares in Q4 2025, an estimated $11K.
  • CRISPR Therapeutics made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #1515 holding.
  • CIBC Private Wealth Group first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 22 quarters since.
  • CIBC Private Wealth Group's CRISPR Therapeutics position peaked at $3.75M in Q1 2021.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.